Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17886605 | 0.87 | ALDH1A1 (0.61) | HSD11B1LMNAGAAPOLBALDH1A1 | |
| SCHEMBL12550380 | 0.76 | HSD11B1 (1.00) | HSD11B1LMNAGAAALDH1A1MAOA | |
| SCHEMBL4402433 | 0.76 | LMNA (0.90) | HSD11B1LMNAGAAPOLBALDH1A1 | |
| SCHEMBL12169363 | 0.76 | LMNA (0.96) | HSD11B1LMNAGAAPOLBALDH1A1 | |
| SCHEMBL10201225 | 0.76 | TDO2 (0.40) | HSD11B1LMNAPOLBALDH1A1 | |
| SCHEMBL4555408 | 0.74 | LMNA (1.00) | HSD11B1LMNAGAAPOLBALDH1A1 | |
| SCHEMBL9906448 | 0.74 | LMNA (1.00) | HSD11B1LMNAGAAPOLBALDH1A1 | |
| SCHEMBL12550300 | 0.73 | LMNA (0.72) | HSD11B1LMNAGAAPOLBALDH1A1 | |
| SCHEMBL12169362 | 0.73 | LMNA (0.73) | HSD11B1LMNAGAAPOLBALDH1A1 | |
| SCHEMBL29505341 | 0.72 | EGLN1 (0.60) | HSD11B1LMNAGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210038599-A1 | SMALL MOLECULE DEGRADERS OF POLYBROMO-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | PBRM1, SMARCC1, SMARCC2 | HSD11B1 3681/4885LMNA 1431/4885GAA 1429/4885 |
| US-20210038599-A1 | SMALL MOLECULE DEGRADERS OF POLYBROMO-1 (PBRM1) | PBRM1, SMARCC1, SMARCC2 | HSD11B1 3681/4885LMNA 1431/4885GAA 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.